

Press release
Leuven / 4 May 2015



QUEST FOR GROWTH

Privak, fixed capital investment company established under Belgian Law

Cartagenia to be acquired by Agilent Technologies

Leuven, May 4th 2015

Agilent Technologies Inc. announced earlier today their intention to acquire 100% of the shares of Cartagenia. The final closing of the transaction is expected mid-May. Cartagenia, a KULeuven spin-off, supplies diagnostic software, database systems, and related services to genetic labs and clinicians, enabling them to perform clinically relevant genetic analyses quickly and efficiently, and offer patients and carers high-quality genetic interpretation and counselling. Agilent (NYSE: A) is a global leader in life sciences, diagnostics and applied chemical markets.

Quest for Growth is an indirect shareholder of Cartagenia through its participation in the Capricorn ICT Arkiv fund. If the transaction is closed successfully Quest for Growth expects a positive impact on its net asset value of approximately 3%.

For more information, please refer to the press release from Agilent attached.

About Quest for Growth

QUEST FOR GROWTH, Privak, Undertaking for Collective Investment with fixed capital under Belgian Law. The diversified portfolio of Quest for Growth is for the most part invested in growth companies listed on European stock exchanges, in European unquoted companies and in venture capital funds. Quest for Growth focuses on innovative companies in sectors such as information- and communication technology (ICT), technology for life sciences (Health-tech) and clean technology (Cleantech). Quest for Growth has been listed on Euronext Brussels since September 23rd 1998. (www.questforgrowth.com)

For further information: Capricorn Venture Partners
Dr Jos B. Peeters, Managing Partner
+32 (0)16 28 41 00



QUEST FOR GROWTH NV

Privak, fixed capital investment company established under Belgian Law
Lei 19 - box 3, B-3000 Leuven - Phone: +32 (0)16 28 41 28 - Fax: +32 (0)16 28 41

www.questforgrowth.com
quest@questforgrowth.com

Agilent Technologies to Acquire Cartagenia, Leading Provider of Software to Enable Clinical Analysis of Genomics Data

SANTA CLARA, Calif., and BOSTON, May 4, 2015 – Agilent Technologies Inc. (NYSE: A) and Cartagenia today announced that they have signed a definitive agreement under which Agilent will acquire Cartagenia, a leading provider of software and services for clinical genetics and molecular pathology labs.

Cartagenia, which has offices in Leuven, Belgium, and Boston, Massachusetts, provides software solutions for variant assessment and reporting of clinical genomics data from next-generation sequencing and microarrays. Uniquely geared to routine clinical labs, Cartagenia's solutions are FDA-registered as exempt Class I Medical Devices in the U.S. and as Class I Medical Devices in Europe. The Cartagenia Bench platform enables technicians, lab directors and clinicians to visualize, assess and report clinical genetics data in the context of patient information.

With Cartagenia Bench, labs can build an internal knowledge base, build variant assessment SOPs, automate report drafting, and access a wide range of community-validated, private and premium content resources, whether for oncology or inherited disease.

Cartagenia's platform also provides deep support for consortia of collaborating labs. Data-sharing has become an essential requirement for the community, and through private and public consortia, users can connect and pool their knowledge on rare diseases and actionable findings.

“Cartagenia's approach to enabling the interpretation of clinical genomics data is revolutionary,” said Jacob Thaysen, president of Agilent's Diagnostics and Genomics Group. “We look forward to providing Cartagenia's software solutions to our clinical genetics and molecular oncology customers and to providing Cartagenia's existing customers with access to our global service and support network. Together, Agilent and Cartagenia can help remove bottlenecks inherent in analysis, interpretation and reporting clinical data—resulting in faster answers for patients.”

“Joining forces with Agilent is an excellent strategic fit and provides tremendous opportunity both for our customers—who will benefit from integration with a broad family of solutions and a range of new applications—and for our team, as we’ll be able to further accelerate our success and growth through Agilent’s global reach and leading footprint in clinical labs,” said Herman Verrelst, chief executive officer, Cartagenia.

The acquisition is expected to be completed May 19, subject to local laws and regulations and customary closing conditions. Cartagenia employs 36 people, all of whom will be offered employment with Agilent.

Financial terms of the transaction were not disclosed.

About Cartagenia

Cartagenia supplies variant assessment support and lab report automation software, database systems, and related services to genetic labs, pathology labs and clinicians, enabling them to perform clinically relevant genetic analyses quickly and efficiently, and offer patients and carers high-quality genetic interpretation and counseling.

Cartagenia Bench Lab allows automation of variant assessment protocols and lab report generation for structural and molecular variant assays such as Arrays, Sanger and Next Generation Sequencing. It supports communication with referring physicians, allows labs and clinicians to put variants in their clinical context, and supports confident data sharing.

The Cartagenia Bench platform is built in collaboration with genetics labs and clinical experts involved in routine medical practice. Because of this, Bench Lab addresses the specific needs of genetic diagnostic labs and clinicians.

Cartagenia Bench is built using a certified ISO13485 Quality Management System and is registered with the FDA as an exempt Class I Medical Device in the United States and as a Class I Medical Device in Europe in conformity with the essential requirements and provisions of the Council Directive 93/42/EEC concerning medical devices, and with the relevant harmonized standards EN ISO62304.

For more information, visit www.cartagenia.com.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A), a global leader in life sciences, diagnostics and applied chemical markets, is the premier laboratory partner for a better world. Agilent works with customers in more than 100 countries, providing instruments, software, services and consumables for the entire laboratory workflow. Agilent generated revenues of \$4.0 billion in fiscal 2014. The company employs about 12,000 people worldwide. Information about Agilent is available at www.agilent.com.

#

NOTE TO EDITORS: Further technology, corporate citizenship and executive news is available at www.agilent.com/go/news.